2017, Number 6
PDF size: 623.29 Kb.
ABSTRACTBackground: Neonatal leukaemia is the one diagnosed in the first 30 days of life. Its incidence is reported in 1 to 5 per million of newborns (it represents less than 1% of leukaemias).
Cases Presentation: We describe all cases diagnosed with neonatal leukaemia between January 1st 1990 and November 1, 2012 at our institution. We searched for all medical records labelled under the diagnosis of leukaemia, and we selected those in which the diagnosis was done in the first 30 days of life. A total of 3,061 medical records were labelled as leukaemia, from which only 5 (0.16%) corresponded to neonatal leukaemia. Affected patients were three females and 2 males with a median age at diagnosis was 21 days (17-26 days). Three cases were acute myeloid leukaemia and two acute lymphoid leukaemia. One patient had Down syndrome. Four patients developed tumoral lysis syndrome. Four patients died at a median age of 84 days (57-176 days). The only survivor patient received complete 50% reduced ATEDox NOPHO protocol, with a last follow-up visit at age 3 years were he has reported free of disease.
Conclusions: We describe the largest cases series in Mexico of neonatal leukaemia.
Vormoor J. Editorial: Leukaemia and cancer in neonates. Semin Fetal Neonatal Med. 2012;17:183-4.
Isaacs H Jr. Tumors of the fetus and newborn. Vol. 35. Philadelphia: WB Saunders; 1997. p. 278-97.
Berry PJ. Congenital tumours. Fetal and Neonatal Pathology. 2nd ed. Berlin: Springer-Verlag; 1993. p. 273-91.
Isaacs H Jr. Congenital and neonatal malignant tumors. A 28 years experience at Children’s Hospital of Los Angeles. Pediatr Hematol Oncol. 1987;9:121-9.
Bader JL, Miller RW. US cancer incidence and mortality in the first year of life. Am J Dis Child. 1979;133:157-9.
Vasilatou-Kosmidis H. Cancer in neonates and infants. Med Pediatr Oncol. 2003;41:7-9.
Cicero Oneto C, Zapata Tarrés M, Flores Toscano K, Flores Montes O. Tumores sólidos malignos neonatales en el Hospital Infantil de México Federico Gómez. Experiencia de 69 años. GAMO. 2013;12:143-9.
Johnson K, Roesler M, Linabery A, Hilden J, Davies S, Ross J. Infant leukemia and congenital abnormalities: A Children's Oncology Group study. Pediatric Blood Cancer. 2010;55:95-9.
Isaacs H Jr. Fetal and neonatal leukemia. J Pediatr Hematol Oncol. 2003;25:348-1.
Bresters D, Reus A, Veerman A, Van Wering E, Van Der Does-van den Berg A, Kaspers G. Congenital Leukaemia: the Dutch experience and review of the literature. Br J Haematol. 2002;117:513-24.
Ishii E, Oda M, Kinugawa N, Oda T, Takimoto T, Suzuki N, et al. Features and outcome of neonatal leukemia in Japan: Experience of the Japan Infant Leukemia Study Group. Pediatr Blood Cancer. 2006;47:268-72.
Brink DS. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. Adv Anat Pathol. 2006;13:256-62.
Sgu XO, Ross JA, Pendergrass T, Reaman G, Lampkin B, Robinson L. Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Childrens Cancer Group Study. J Natl Cancer Inst. 1996;88:24-31.
Robinson LL, Buckley JD, Daigle AE et al. Maternal drug use and risk of childhooldnonlumphoblasticleukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Children´s Cancer Study Group). Cancer. 1989;63:1904-11.
Hess JL, Yu BD, Li B et al. Defects in yolk sac hematopoiesis in M11-null embryos. Blood. 1997;90:1799-1806.
Foucar K, Friedman K, Llewellyn A et al. Prenatal diagnosis of myeloproliferative disorder via percutaneous umbilical blood sampling. Report of two cases in fetuses affected by Down´s syndrome. Am J Pathol. 1992;97:584-90.
Rendón García H, Covarrubias Espinoza G, Ornelas Sánchez M, Rivera Gómez R. Leucemia del Recién Nacido. Bol Clin Hosp Infant Edo Son. 2006;23:98-101.
Miranda H, Cardiel L, Verdusco M, Durán MA, Bolea V, Reynoso E et al. Un caso de leucemia congénita y revisón del tema. Rev Mex Pediatr. 2002;69;201-5.